Senior Manager, Digital Centric Commercialization (DCC) Analytics and Operations at Axsome Therapeutics, Inc. | New York, USA | $140K/yr – $160K/yr | SalaryGuide

Marketing Jobs
General Marketing
Senior Manager, Digital Centric Commercialization (DCC) Analytics and Operations

Axsome Therapeutics, Inc.

Senior Manager, Digital Centric Commercialization (DCC) Analytics and Operations

New York, USA (Hybrid)

$140K/yr – $160K/yrSenior Level6+ years expFull time

Posted 7 weeks ago

Job Summary

Original Job Description

Axsome Therapeutics, Inc.

Glassdoor

3.7

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options.Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are intensely committed to developing products that meaningfully improve the lives of patients and provide additional therapeutic options for physicians.

Marketing team

–

Employees

–

Headquarters

New York, New York, USA

Founded

2012

Employee Sentiment

Overall Rating

3.7 / 5

Recommend to a Friend

64%

CEO Approval

72%

Source: Glassdoor

Traffic Signals

Monthly Google Ads Budget

$0.0

Marketing Team

Marketing Roles Posted (Last 30 Days)

1

Funding

Total Funding

$1.0B

Last Raise

10 months ago

Last Raise Amount

$570.0M

2025-05-13
Post IPO Debt • $570.0M
2023-06-28
Post IPO Equity • $225.0M
2019-12-23
Post IPO Equity • $200.0M

Recent News

Quiver Quantitative

Axsome Therapeutics to Present at Key Investor Conferences in December 2025

Axsome Therapeutics (NASDAQ: AXSM) to present at Piper Sandler and BofA CNS events

Axsome Therapeutics Inc. recovery potential after sell off

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Avenue (OTC: ATXI): Axsome to acquire Baergic; up to $82M milestones, royalties

Axsome adds AstraZeneca epilepsy candidate to pipeline through Avenue subsidiary acquisition

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Axsome acquires global rights to AstraZeneca’s epilepsy drug candidate

Mizuho Maintains Axsome Therapeutics (AXSM) Outperform Recommendation

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Axsome therapeutics CEO Tabuteau sells $21.8 million in AXSM stock

Is Axsome Therapeutics Set for More Gains After 54% Rally and Clinical Pipeline News?

Morgan Stanley Maintains Axsome Therapeutics (AXSM) Overweight Recommendation

Axsome Therapeutics Saw Sales Jump But Losses Remain

Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Axsome Therapeutics Reports Strong Q3 2025 Growth

Axsome Therapeutics Q3 2025 slides: Strong revenue growth amid pipeline expansion

Axsome Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Axsome Therapeutics (AXSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

How rising interest rates impact Axsome Therapeutics Inc. stock - Weekly Market Summary & Comprehensive Market Scan Insights

Is Axsome Therapeutics Inc. stock a buy on dips - Gap Up & Weekly Momentum Stock Picks

Axsome Therapeutics (NASDAQ: AXSM) to join Truist, Guggenheim and UBS conferences in November

Is Axsome Therapeutics Inc. (19X) stock positioned for digital growth era - Quarterly Trade Review & Risk Controlled Daily Plans

Is Axsome Therapeutics Inc. forming a reversal pattern - Quarterly Profit Summary & High Conviction Buy Zone Picks

Axsome Therapeutics Inc. stock volume spike explained - July 2025 Sentiment & Expert Verified Movement Alerts

DirectorsTalk Interviews

Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Investors Eye 39% Potential Upside with Strong Buy Ratings

Aberdeen Group plc Purchases 17,962 Shares of Axsome Therapeutics, Inc. $AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Buy" from Analysts

KLP Kapitalforvaltning AS Raises Position in Axsome Therapeutics, Inc. $AXSM

Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating

Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community

1 in 5 U.S. adults affected — Axsome Recognizes Mental Illness Awareness Week and shares NAMI resources

Axsome therapeutics CEO sells $5.4m in shares

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

B. Riley Securities Initiates Coverage of Axsome Therapeutics (AXSM) with Buy Recommendation

Can Auvelity Drive Axsome's Growth Through the Rest of 2025?

Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (2020-2034) | DelveInsight

Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (2020-2034) | DelveInsight

Axsome Therapeutics Insider Sold Shares Worth $1,159,600, According to a Recent SEC Filing

Axsome therapeutics COO Jacobson sells $1.15 million in shares

How Investors May Respond To Axsome Therapeutics (AXSM) Showcasing Late-Stage CNS Pipeline Data at Psych Congress

Transcript : Axsome Therapeutics, Inc. Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, Sep-17-2025 08

Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025

Axsome Therapeutics COO sells shares for $5.2 million

Quiver Quantitative

Axsome Therapeutics Highlights Key Presentations at Psych Congress 2025 on CNS Disorders and Innovative Treatment Approaches

Axsome Therapeutics Insider Sold Shares Worth $7,361,891, According to a Recent SEC Filing

Axsome Therapeutics, Inc.

Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025

Axsome therapeutics CEO Tabuteau sells $7.3m in shares

Axsome Therapeutics COO Sells All Common Stock Holdings

Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm

Axsome therapeutics director Coleman buys $200k+ in shares

Axsome therapeutics director Saad sells $1.14 million in shares

Axsome Therapeutics Director Sells Shares

The Motley Fool

Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years

Axsome initiated with Overweight at Wells Fargo on Alzheimer's drug potential

Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?

Axsome Therapeutics stock rated Overweight by Wells Fargo

Axsome Therapeutics Insider Sold Shares Worth $7,303,400, According to a Recent SEC Filing

H.C. Wainwright Reaffirms Buy on Axsome (AXSM) Following Generic Challenge to Portfolio

Axsome Shares Up 20% in a Month: How Should You Play the Stock?

Axsome Therapeutics Director Sells 60,000 Shares

Major CNS Biotech Axsome Therapeutics Set for 6 High-Profile Healthcare Conferences in September 2025

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics, Inc.

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics receives notice of proposed generic for Symbravo

Axsome Therapeutics Receives Paragraph IV Certification Notice

AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

Axsome Therapeutics’ Earnings Call Highlights Robust Growth

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings

Axsome Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:AXSM) 2025-08-04

Axsome Therapeutics, Inc. SEC 10-Q Report

Earnings call transcript: Axsome Therapeutics beats Q2 2025 forecasts

Axsome Therapeutics Reports Strong Q2 2025 Growth

Axsome Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025

Axsome Therapeutics's Q2 revenue rises 72% to $150 mln

Axsome Therapeutics reports Q2 EPS (97c), consensus ($1.09)

Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Transcript : Axsome Therapeutics, Inc., Q2 2025 Earnings Call, Aug 04, 2025

Quiver Quantitative

AXSOME THERAPEUTICS Earnings Preview: Recent $AXSM Insider Trading, Hedge Fund Activity, and More

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Axsome: Some Recent Setbacks, Some Recent Wins — Still A Buy (NASDAQ:AXSM)

Axsome Therapeutics Rings the Opening Bell

Axsome Reveals New Phase 3 Data for 6 Major Brain Disorders: Expert Panel Discusses Breakthrough Treatments

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

Axsome Therapeutics, Inc.

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

Axsome Therapeutics, Inc.

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

Research and Markets

Agitation in Alzheimer's Disease Research Report 2025-2035 | Market Expands with Shift Toward Targeted Therapies, Holistic Care Models, and Non-Pharmacological Interventions

Investors ignore increasing losses at Axsome Therapeutics (NASDAQ:AXSM) as stock jumps 4.5% this past week

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

Mark Your Calendar: CNS Leader Axsome Therapeutics Q2 Earnings Call - Key Details Inside

Axsome Therapeutics Scheduled to Report Q2 2025 Financial Results and Host Conference Call on August 4, 2025

Axsome Therapeutics R&D Day: Key Opinion Leaders to Reveal Next-Gen CNS Treatment Innovations

Axsome Therapeutics to Host Frontiers in Brain Health R&D Day on July 21, 2025

Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating

Axsome therapeutics’ general counsel sells $2.28 million in stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM): When Will It Breakeven?

Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market

Similar Jobs

Marketing Director

MarkeTilt

USA (Remote)

In-houseFull-timeSenior level

Marketing Specialist, Accident & Health

Zurich Insurance

Will County, IL (Remote)

$76K/yr - $124K/yrIn-houseFull-timeMid level3+ years exp.

Marketing Intern

Specialityvalve

USA (Remote)

In-houseFull-timeIntern/new grad

Associate Director, Content

Walker Sands

Boston, MA (Hybrid)

$94K/yr - $98K/yrAgencySenior level6+ years exp.

Marketing Specialist

Isabella Stewart Gardner Museum

Boston, MA (On-site)

$60K/yr - $70K/yrIn-houseFull-timeMid level5+ years exp.

Regional Director of Marketing

Five Iron Golf

New York, USA (Hybrid)

$120K/yr - $150K/yrIn-houseFull-timeDirector/executive6+ years exp.

View more General Marketing jobs

Similar Jobs

View more General Marketing jobs

Marketing Director

MarkeTilt

USA (Remote)

In-houseFull-timeSenior level

Marketing Specialist, Accident & Health

Zurich Insurance

Will County, IL (Remote)

$76K/yr - $124K/yrIn-houseFull-timeMid level3+ years exp.

Marketing Intern

Specialityvalve

USA (Remote)

In-houseFull-timeIntern/new grad

Associate Director, Content

Walker Sands

Boston, MA (Hybrid)

$94K/yr - $98K/yrAgencySenior level6+ years exp.

Marketing Specialist

Isabella Stewart Gardner Museum

Boston, MA (On-site)

$60K/yr - $70K/yrIn-houseFull-timeMid level5+ years exp.

Regional Director of Marketing

Five Iron Golf

New York, USA (Hybrid)

$120K/yr - $150K/yrIn-houseFull-timeDirector/executive6+ years exp.

View more General Marketing jobs

SalaryGuide^™

The career intelligence platform for marketing professionals.

By Category

General Marketing Jobs
Social Media Jobs
Communications Jobs
Product Marketing Jobs
Growth Marketing Jobs
Event Marketing Jobs
Content Marketing Jobs
Public Relations Jobs
Paid Media Jobs
Community Management Jobs
View All Marketing Jobs

Remote Jobs

Remote General Marketing Jobs
Remote Social Media Jobs
Remote Communications Jobs
Remote Product Marketing Jobs
Remote Growth Marketing Jobs
Remote Event Marketing Jobs
Remote Content Marketing Jobs
Remote Public Relations Jobs
Remote Paid Media Jobs
Remote Community Management Jobs
View All Remote Marketing Jobs

By Work Style

Remote Marketing Jobs
On-Site Marketing Jobs
Hybrid Marketing Jobs

By Company Type

In-House Marketing Jobs
Marketing Agency Jobs

By Industry

Software
SaaS
Information Technology
Health Care
Financial Services
E-Commerce
Retail
Professional Services
Consulting
Media and Entertainment
Education
Real Estate
All industries

By Experience

Entry-Level Marketing Jobs
Mid-Level Marketing Jobs
Senior Marketing Jobs
Marketing Manager Jobs
Marketing Director Jobs

By Employment

Full-Time Marketing Jobs
Part-Time Marketing Jobs
Contract Marketing Jobs
Marketing Internships

Quick Links

Browse All Jobs
Salary Data
Companies
About Us
Contact Us

SalaryGuide^™

The #1 job board for marketing professionals. Find your next role in paid media, SEO, content, and more.

© 2025 SalaryGuide. All rights reserved.

Privacy PolicyTerms of ServiceRefund PolicyContact